Alkermes 3Q Revenues: $154.5 million (+14%) 3Q Earnings: $18.1 million (+11%) YTD Revenues: $432.9 million (+5%) YTD Earnings: $17.6 million (-20%) Comments: Manufacturing and royalty revenues in the quarter were $132.7 million, up 12%, driven by the atypical antipsychotic franchise, up 36% to $71.2 million. Product sales were $20.6 million, up 29% driven by and VIVITROL, with sales up 30% to $20.6 million. R&D revenues were $1.2 million, down 31%....